Volume 5.27 | Jul 22

Pancreatic Cell News 5.27 July 22, 2014
Pancreatic Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Pancreatic Cell News on Twitter
Human IAPP-Induced Pancreatic β Cell Toxicity and Its Regulation by Autophagy
Researchers demonstrate that treatment of INS-1 cells with human islet amyloid polypeptide (IAPP) enhances cell death, inhibits cytoproliferation, and increases autophagosome formation. Furthermore, inhibition of autophagy increased the vulnerability of β cells to the cytotoxic effects of human IAPP. [J Clin Invest]
Full Article
Differentiation Doesn't Have to be Difficult - Get Easy, Standardized hPSC Differentiation
PUBLICATIONS (Ranked by impact factor of the journal)

Progesterone Receptor Membrane Component 1 Is a Functional Part of the GLP-1 Receptor Complex in Pancreatic Beta Cells
To better understand the mechanisms that control the insulinotropic actions of glucagon-like peptide-1 (GLP-1), affinity purification and mass spectrometry (AP-MS) were employed to uncover potential proteins that functionally interact with the GLP-1R receptor (GLP-1R). AP-MS performed on Chinese hamster ovary cells or MIN6 beta cells, both expressing the human GLP-1R, revealed 99 proteins potentially associated with GLP-1R. [Mol Cell Proteomics] Abstract

A Phenylpropenoic Acid Glucoside Phytochemical Augments Pancreatic Beta Cell Mass in High-Fat Diet-Fed Mice and Protects Beta Cells from ER Stress-Induced Apoptosis
In vitro, phenylpropenoic acid glucoside protected beta cells from palmitate-induced apoptosis. It protected beta cells against endoplasmic reticulum (ER) stress by increasing expression of anti-apoptotic BCL2 protein without affecting pro-apoptotic signals. [Mol Nutr Food Res] Abstract

The Melatonin Agonist Ramelteon Induces Duration-Dependent Clock Gene Expression through cAMP Signaling in Pancreatic INS-1 β-Cells
In rat INS-1 cells, a pancreatic β-cell line endogenously expressing melatonin receptors, ramelteon persistently decreased cAMP element-binding protein (CREB) phosphorylation during the treatment period, whereas the subsequent washout induced an enhancement of forskolin-stimulated CREB phosphorylation in a duration- and concentration-dependent manner. [PLoS One] Full Article

Expression of Nucleobindin 1 (NUCB1) in Pancreatic Islets and Other Endocrine Tissues
Using reverse transcription plus the polymerase chain reaction and Western blot, scientists demonstrate that NUCB1 is present in the endocrine islets of Langerhans but absent from the exocrine acinar cells. [Cell Tissue Res] Abstract

Interferon Stimulated Gene 15 Has an Anti-Apoptotic Effect on MIN6 Cells
Researchers used the mouse beta cell line MIN6 to investigate the role of interferon stimulated gene (ISG)15 and paid special attention to apoptosis. Although not detected in native MIN6 cells, free ISG15 and ISG15 conjugated proteins were both present in dose-dependently increased amounts following stimulation with interferon alpha. [Endocr J] Abstract | Full Article


Nitric Oxide Increases the Invasion of Pancreatic Cancer Cells via Activation of the PI3K-AKT and RhoA Pathways after Carbon Ion Irradiation
Irradiation of PANC-1 cells promoted invasion and production of nitric oxide, which activated the PI3K-AKT signaling pathway, while independently activating RhoA. [FEBS Lett] Full Article

Expression of Akt Kinase-Interacting Protein 1, a Scaffold Protein of the PI3K/PDK1/Akt Pathway, in Pancreatic Cancer
The expression of Akt kinase-interacting protein 1 (Aki1) and its associated proteins was assayed in pancreatic cancer cell lines, and its involvement in cell viability was examined by treatment with Aki1 small interfering RNA. All of the pancreatic cancer cell lines expressed Aki1 and its associated proteins at various levels. [Pancreas] Abstract

Transferrin Surface-Modified PLGA Nanoparticles-Mediated Delivery of a Proteasome Inhibitor to Human Pancreatic Cancer Cells
Researchers developed a drug delivery system based on poly(lactic-co-glycolic acid) (PLGA) nanoparticles for an efficient and targeted action of the proteasome inhibitor bortezomib against pancreatic cancer cells. [J Biomed Mater Res A] Abstract

[Free Webinar] A Guide To Successful Flow Cytometry Analysis of ALDHbr Cells - Watch Now.
Pancreatic Cancer Organotypics: High Throughput, Preclinical Models for Pharmacological Agent Evaluation
The authors discuss the evolution of 3D organotypic models, which recapitulates the morphological and functional features of pancreatic ductal adenocarcinoma (PDAC). Organotypic cultures are a valid high throughput preclinical in vitro models that may be a useful tool to help establish new therapies for PDAC. [World J Gastroenterol] Full Article

Visit our reviews page to see a complete list of reviews in the pancreatic cell research field.
Lexicon and JDRF Collaborate for Phase II Clinical Trial of LX4211 in Type 1 Diabetes
Lexicon Pharmaceuticals, Inc. announced that JDRF will provide funding to support a Phase II, randomized, double-masked, placebo-controlled clinical trial to evaluate the efficacy and safety of LX4211 in a younger population with type 1 diabetes. [Lexicon Pharmaceuticals, Inc.] Press Release

ViaCyte Files Investigational New Drug Application and Device Master File with FDA for Novel Cell Replacement Therapy Product Candidate Designed to Treat Patients with Type 1 Diabetes
ViaCyte, Inc. announced that it has filed an investigational new drug application with the United States Food and Drug Administration (FDA) seeking to initiate a Phase I/II clinical trial in patients with type 1 diabetes. [ViaCyte, Inc.] Press Release

Aduro BioTech Receives Breakthrough Therapy Designation from FDA for Innovative Pancreatic Cancer Combination Immunotherapy
Aduro BioTech, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation for its pancreatic cancer combination treatment that consists of its CRS-207 and GVAX pancreas immunotherapies. [Aduro BioTech, Inc. (Business Wire)] Press Release

Completion of Recruitment for Phase IIa Trial
Silence Therapeutics plc has completed the recruitment of patients for its Phase IIa trial of Atu027 in pancreatic cancer. [Silence Therapeutics plc] Press Release

From our sponsor:
Looking for ALDH+ cancer stem cells?
Watch a video to see how ALDEFLUOR™ can help.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Biology and Treatment of Metastatic Cancers
September 23-26, 2014
El Jadida, Morocco

Visit our events page to see a complete list of events in the pancreatic cell community.
NEW Product Marketing Manager (Cesca Therapeutics)

Postdoctoral Research Assistant – Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy for Pancreatic Cancer Stem Cells (Queen Mary University of London)

Associate Director of Global Marketing – Pancreatic Cancer (Celgene Corporation)

Professorship – Molecular Mechanisms of Diabetes Pathogenesis (University of Southern Denmark)

Postdoctoral Fellow – Metabolism (University of Copenhagen)

PhD Scholarships – Diabetes (Danish Diabetes Academy)

Diabetes UK RD Lawrence Fellowships (Diabetes UK)

Postdoctoral Fellow – Mechanisms that Drive Gastrointestinal Malignancies (Washington University School of Medicine)

Postdoctoral Fellowship – Calcium Signaling (Brigham & Women’s Hospital – Harvard Medical School)

Scientist – Pluripotent Stem Cell Biology Endoderm Lineages (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Pancreatic Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Pancreatic Cell News: Archives | Events | Contact Us